Integer Holdings Co. (NYSE:ITGR) Shares Sold by Pitcairn Co.

Pitcairn Co. cut its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 12.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,165 shares of the medical equipment provider’s stock after selling 895 shares during the period. Pitcairn Co.’s holdings in Integer were worth $801,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ITGR. Vanguard Group Inc. raised its stake in Integer by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 3,826,088 shares of the medical equipment provider’s stock valued at $446,428,000 after acquiring an additional 23,382 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in shares of Integer by 4.0% during the first quarter. CANADA LIFE ASSURANCE Co now owns 35,068 shares of the medical equipment provider’s stock valued at $4,091,000 after purchasing an additional 1,361 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Integer by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,031 shares of the medical equipment provider’s stock valued at $2,221,000 after purchasing an additional 1,219 shares in the last quarter. Hancock Whitney Corp acquired a new stake in Integer in the first quarter worth about $203,000. Finally, Virtu Financial LLC bought a new position in Integer in the 1st quarter valued at about $298,000. 99.29% of the stock is owned by institutional investors.

Integer Price Performance

ITGR stock opened at $138.11 on Monday. Integer Holdings Co. has a one year low of $84.75 and a one year high of $140.91. The firm has a 50-day moving average of $130.22 and a two-hundred day moving average of $123.57. The firm has a market capitalization of $4.63 billion, a PE ratio of 42.63, a P/E/G ratio of 1.95 and a beta of 1.09. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. During the same quarter in the prior year, the firm earned $1.27 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts forecast that Integer Holdings Co. will post 5.34 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on ITGR. Truist Financial dropped their price target on shares of Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. KeyCorp upped their target price on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Bank of America upped their price target on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $140.00 price objective (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Finally, Citigroup raised their target price on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $139.75.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.